Every road leads to Rome: therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes.

Abstract

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease. Whether extracellular vesicles are effective in treating IPF and what is the optimal administrative route is not clear. Our previous studies have shown that immunity and matrix regulatory cells (IMRCs) derived from human embryonic stem cells can safely treat lung injury and fibrosis in mouse models, and its mechanism of action is related to the paracrine effect. In this study, we investigated the therapeutic effects of IMRC-derived extracellular vesicles (IMRC-EVs) on a bleomycin-induced pulmonary fibrosis mouse model and explored the optimal route of administration.

METHODS:

To study the biodistribution of IMRC-EVs after administration via different routes, NIR labeled-IMRC-EVs were delivered by intratracheal (IT) or intravenous (IV) route, and in vivo imaging was acquired at different time points. The therapeutic effects of IMRC-EVs delivered by different routes were analyzed by assessing histology, lung function, cytokines levels, and transcriptome profiling. RNA-seq of lung tissues was performed to investigate the mechanisms of EV treatment through IT or IV administrations.

RESULTS:

IMRC-EVs mainly reserved in the liver and spleen when administrated via IV route; and mainly retained in the lungs via the IT route. IMRC-EVs administrated via both routes demonstrated a therapeutic effect as attenuated pulmonary fibrosis, improved lung function, and histological parameters. Based on our RNA-seq results, different pathways may be affected by IMRC-EVs administrated via IT or IV routes. In addition, in vitro experiments showed that IMRC-EVs inhibited epithelial-to-mesenchymal transition induced by TGF-β.

CONCLUSION:

IMRC-EVs administrated via IT or IV routes generate different biodistributions, but are both effective for the treatment of bleomycin-induced pulmonary fibrosis. The therapeutic mechanisms of IMRC-EVs administrated via different routes may be different.

• Authors: Shengnan Yang, Peipei Liu, Tingting Gao, Dingyun Song, Xinyu Zhao, Yupeng Li, Jun Wu, Liu Wang, Zai Wang, Jie Hao, Chen Wang, Huaping Dai
• Journal: Stem cell research & therapy (Stem Cell Res Ther) Vol. 13 Issue 1 Pg. 163 (04 12 2022) ISSN: 1757-6512 [Electronic] England
• PMID: 35413874 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Bleomycin

Topics

• Animals
• Bleomycin
• Disease Models, Animal
• Extracellular Vesicles (metabolism)
• Human Embryonic Stem Cells (metabolism)
• Humans
• Idiopathic Pulmonary Fibrosis (metabolism)
• Mesenchymal Stem Cells (metabolism)
• Mice
• Rome
• Tissue Distribution